Trial Profile
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Pharmacodynamics
- Acronyms SOCRATES-REDUCED
- Sponsors Bayer
- 15 Jul 2022 Pooled data from SOCRATES-REDUCED and VICTORIA studies evaluating the pharmacokinetics of Vericiguat, published in the Clinical Pharmacology and Therapeutics.
- 04 Jun 2021 Results of population pharmacokinetics and pharmacodynamics of vericiguat published in the Clinical Pharmacokinetics.
- 08 Nov 2015 Results published in the JAMA: the Journal of the American Medical Association